|
|
|
| Effect and safety study of glucocorticoid in different administration methods in the treatment of acute exacerbation of chronic obstructive pulmonary disease |
| ZHANG Shao-xin1 GUO Ling-ling2 |
1.Department of Infectious Disease,People′s Hospital of Lianxi District of Jiujiang City in Jiangxi Province,Jiujiang 332005,China;
2.Drug Rehabilitation Center of Jiujiang City in Jiangxi Province,Jiujiang 332012,China |
|
|
|
|
Abstract ObjectiveTo investigate the efficacy and safety of glucocorticoid in oral administration and intravenous infusion in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).MethodsA total of 102 patients with AECOPD who were enrolled in our hospital from October 2015 to December 2016 were selected as research objects.They were evenly divided into the oral administration group and the intravenous infusion group according to a random number table method.In the oral administration group,32 mg/d Methylprednisolone was used,while in the intravenous infusion group,Methylprednisolone via intravenous drip was adopted.The dose in the first three days was 1 mg/(kg·d),and 0.5 mg/(kg·d)from day 4 to day 7.After one-week treatment,the efficacy was assessed and the occurrence of adverse reactions in the two groups was compared.ResultsThere was no significant difference in the total effective rate between the two groups(P＞0.05).The level of PaO2and PaCO2after treatment in the two groups was significantly better than that before treatment,with significant difference (P＜0.01).There was no significant difference in the level of pH,PaO2and PaCO2before treatment and after treatment between the two groups(P＞0.05).There was no significant difference in the incidence of digestive tract reaction between the two groups(P＞0.05).The incidence rate of elevated blood glucose,elevated blood pressure,and pulmonary encephalopathy in the oral administration group was significantly lower than that in the intravenous infusion group,with significant difference (P＜0.05).ConclusionGlucocorticoid both in oral administration and in intravenous infusion obtain satisfactory effect on treating AECOPD,but the oral administration has less complications and higher safety.
|
|
|
|
|
|
| [1] |
Leuppi JD，Schuetz P，Bingisser R，et al.Short-term vs.conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease the reduce randomized clinical trial[J].JAMA，2013，309（21）：2223-2231.
|
| [2] |
曾海萍，黄健，李珂佳，等.某院慢性阻塞性肺疾病急性加重期全身应用糖皮质激素情况分析[J].中国药业，2014，23（10）：66-69.
|
| [3] |
金珊珊，陈小岚，刘刚，等.糖皮质激素对COPD及ARDS患者 IL-8 表达的干预作用[J].医学综述，2015，21（20）：3668-3670.
|
| [4] |
Casaburi R，Briggs DD，Donohue JF，et al.The spirometric efficacy of once daly dosing with tiotropium in stable COPD：a 13-week multicenter trial.The US Tiotropium Study Group[J].Chest，2013，118（5）：1294-1302.
|
| [5] |
张永梅，肖成志.中西医结合治疗对COPD急性加重期患者肺功能改善和免疫功能的影响[J].海南医学院学报，2015，21（1）：73-76.
|
| [6] |
邱勤，文富强.布地奈德与糖皮质激素对老年AECOPD合并Ⅱ型糖尿病患者的疗效对比研究[J].西部医学，2016，28（4）：479-482，486.
|
| [7] |
孙虎，左蕾，叶远征，等.全身应用糖皮质激素对慢性阻塞性肺疾病急性加重患者治疗效果的系统评价[J].中国呼吸与危重监护杂志，2017，16（1）：1-8.
|
| [8] |
王晓兵，宋志军，刘巍.糖皮质激素不同疗程用药在COPD急性加重期治疗中的应用观察[J].河北医药，2015，37（18）：2805-2807.
|
| [9] |
Criner GJ，Bourbeau J，Diekemper RL，et al.Prevention of acute exacerbations of COPD：American college of chest physicians and Canadian thoracic society guideline[J].Chest，2015，147（4）：894-942.
|
| [10] |
尹义平，周琴，刘晓帆，等.糖皮质激素两种给药方法治疗急性加重期慢性阻塞性肺疾病62例[J].医药导报，2014，33（4）：461-463.
|
| [11] |
王慎临，陈更业.糖皮质激素治疗慢性阻塞性肺疾病急性加重期的效果观察[J].宁夏医学杂志，2014，36（5）：424-426.
|
| [12] |
孙惠萍，徐惠娟，戴加乐.糖皮质激素不同给药方式对急性加重期慢性阻塞性肺疾病治疗的有效性和安全性[J].中国医药导报，2016，13（1）：130-136.
|
| [13] |
陈小岚，金珊珊，王兴友.慢性阻塞性肺疾病急性加重期应用糖皮质激素治疗的进展[J].医学综述，2015，21（9）：1636-1639.
|
| [14] |
龚建化，何丽，张家洪，等.糖皮质激素不同给药方式治疗慢性阻塞性肺疾病急性加重期患者的临床研究[J].实用医学杂志，2013，29（20）：3325-3328.
|
| [15] |
吴刚.糖皮质激素不同给药方式对AECOPD患者炎症因子及肺功能的影响[J].临床肺科杂志，2016，21（11）：2018-2020.
|
|
|
|
